- Home
- SEVN vs NKTX Comparison
SEVN vs NKTX Comparison
Compare SEVN & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- NKTX
- Stock Information
- Founded
- SEVN 1986
- NKTX 2015
- Country
- SEVN United States
- NKTX United States
- Employees
- SEVN N/A
- NKTX N/A
- Industry
- SEVN Real Estate Investment Trusts
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- SEVN Real Estate
- NKTX Health Care
- Exchange
- SEVN Nasdaq
- NKTX Nasdaq
- Market Cap
- SEVN 149.0M
- NKTX 147.7M
- IPO Year
- SEVN N/A
- NKTX 2020
- Fundamental
- Price
- SEVN $9.46
- NKTX $2.11
- Analyst Decision
- SEVN Strong Buy
- NKTX Strong Buy
- Analyst Count
- SEVN 2
- NKTX 5
- Target Price
- SEVN $13.50
- NKTX $13.50
- AVG Volume (30 Days)
- SEVN 122.0K
- NKTX 1.4M
- Earning Date
- SEVN 10-27-2025
- NKTX 11-07-2025
- Dividend Yield
- SEVN 11.84%
- NKTX N/A
- EPS Growth
- SEVN N/A
- NKTX N/A
- EPS
- SEVN 1.04
- NKTX N/A
- Revenue
- SEVN $29,408,000.00
- NKTX N/A
- Revenue This Year
- SEVN N/A
- NKTX N/A
- Revenue Next Year
- SEVN N/A
- NKTX N/A
- P/E Ratio
- SEVN $9.12
- NKTX N/A
- Revenue Growth
- SEVN N/A
- NKTX N/A
- 52 Week Low
- SEVN $9.22
- NKTX $1.31
- 52 Week High
- SEVN $13.97
- NKTX $3.81
- Technical
- Relative Strength Index (RSI)
- SEVN 33.22
- NKTX 45.24
- Support Level
- SEVN $9.23
- NKTX $2.04
- Resistance Level
- SEVN $10.90
- NKTX $2.47
- Average True Range (ATR)
- SEVN 0.29
- NKTX 0.18
- MACD
- SEVN -0.10
- NKTX -0.04
- Stochastic Oscillator
- SEVN 13.77
- NKTX 10.64
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.